CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Conditions: Metastatic Melanoma; Renal Cell Carcinoma; Colon Cancer With MSI-H or dMMR Interventions: Drug: CD24Fc; Drug: Ipilimumab; Drug: Nivolumab Sponsors: OncoImmune, Inc.; Huntsman Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials